Vertex Pharmaceuticals is set to release its Q2 earnings results this evening, amidst a backdrop of a billion-dollar acquisition strategy, the launch of a groundbreaking pain medication, and a nephrology pipeline that is currently expedited by the FDA. This comes at a time when the first earnings per share consensus is projected to fall below levels seen in the same period last year.